Cypress To Continue PROSORBA Trial
Cypress Bioscience is to continue its trial of the PROSORBA column inrheumatoid arthritis, following a recommendation from an independent US Data Safety and Monitoring Board which reviewed interim results from the first 63 severe refractory RA patients in a pivotal trial.
Cypress instructed the DSMB to evaluate the product based on its safety profile and a set efficacy threshold. The company remains blinded to the results, but will continue the trial, which it expects to complete by the end of 1998. The DSMB has recommended that the second interim analysis be conducted once 90 patients have been treated, with about 250 patients in total expected to be enrolled.
PROSORBA is already approved in the USA for the treatment of idiopathic thrombocytopenic purpura. An approval for the treatment of RA would mean entry into an estimated $2 billion market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze